Background: Hepatitis B is a major global health problem. Chronic hepatitis characterized by hepatic inflammation, necrosis and persistence of HbsAg for at least 6 months. liver disease more predictably associated with impaired metabolism drugs than acute dysfunction. Prescribing in patients chronic challenging because concerns that the drug may exacerbate disease. There also fear altered state...

The safety and efficacy of perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma and low serum levels of hepatitis B virus DNA are unknown. This retrospective study compared serum levels of hepatitis B virus DNA, liver function, morbidity, and length of hospital stay between patients who underwent hepatic resection alone and patients who received e...

Objective. To determine the efficacy and safety of Lingmao Formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase (ALT). Methods. 301 patients were randomly assigned to receive Lingmao Formula combined with entecavir (treatment group) or placebo combined with entecavir (control group) for 52 weeks. The outcomes of interest i...

conclusions etv and lam treatments had similar effects to improve 24 weeks survival rate of patients with chb-associated liver failure, but etv was associated with greater clinical improvement. both drugs were tolerated well during the treatment. it is suggested to perform further studies to verify the results. background nucleoside analogues are recommended as antiviral treatments for patients...

conclusions we discovered a consistent reduction of serum ace levels by two oral antiviral monotherapies, entecavir and telbivudine. serum ace levels were negatively correlated with egfrs in telbivudine treated patients. objectives we aimed to investigate changes in serum protein abundances associated with renal function in response to antiviral treatments. materials and methods primarily, a tr...

BACKGROUND As new treatment options for chronic hepatitis B virus (HBV) become available, evaluations of cost-effectiveness become important. Entecavir is a deoxyguanine nucleoside analogue approved by the U.S. Food and Drug Administration in March 2005 for HBV infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (...

OBJECTIVE To conduct a cost-effectiveness analysis of currently available nucleos(t)ide antiviral treatments (lamivudine, telbivudine, entecavir, and tenofovir) for chronic hepatitis B in Canada. METHODS Markov modeling was used to project the lifetime health benefits and costs associated with the antiviral treatments. The hypothetical patient population was hepatitis B e antigen-positive chr...

BACKGROUND/AIMS We aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir treatment in patients with chronic hepatitis B virus (HBV) infection. MATERIALS AND METHODS This study was designed as a retrospective multicenter cohort study. The impact of hepatosteatosis on pre-treatment serum HBV DNA levels and a...

The present study aimed to investigate the possible mechanisms underlying the effect of modified Xiaochaihu decoction (mXCHD) in the treatment of chronic hepatitis B (CHB). Patients with CHB, in addition to liver stagnation and spleen deficiency syndrome were randomly assigned to receive either Chinese (mXCHD) or western (entecavir) treatment, with 30 cases in each group. Serum was collected fo...